UN chief urges tech sector to power data centers with renewables
WASHINGTON (Reuters) -U.N. Secretary General António Guterres on Tuesday called on tech companies to power the build out of data centers with 100% renewable energy by 2030, even as the industry turns to gas and coal-fired power plants to meet surging demand.
The secretary general made his case for why he believes energy-hungry data centers should lock in a future of clean energy, saying the transition to renewable energy is inevitable, even as some countries and companies still embrace fossil fuels.
"The future is being built in the cloud," Guterres said in a speech at the United Nations' headquarters in New York. "It must be powered by the sun, the wind, and the promise of a better world."
His appeal to technology companies comes a day before U.S. President Donald Trump unveils his administration's AI Action Plan, which is expected to contain a number of executive actions aimed at easing restrictions on land use and energy production to unleash artificial intelligence development.
Trump has declared a national energy emergency to address the vast amounts of energy needed by data centers to power AI to compete with China and enable him to ease environmental restrictions to build more power plants fueled by gas, coal and nuclear.
Top economic rivals, the U.S. and China, are locked in a technological arms race over who can dominate AI.
At the same time, Trump has issued executive orders and signed the One Big Beautiful Bill Act that curtails the use of incentives for wind and solar energy, which dominate the queue of new power generation waiting to connect to the electric grid.
Guterres also appealed to governments to ready new national climate plans to deliver the goals of the Paris climate agreement by September that will lock-in a transition away from fossil fuels.
He said this moment is an opportunity for governments to meet all new electricity demand with renewables and use water sustainably in cooling systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Amazon shoppers are obsessed with this 'lifesaver' power bar — it's still on sale for its Prime Day price
This power bar allows you to plug in and charge up to nine devices at once. Amazon Prime Day is over, but savvy shoppers know there are still hundreds of deals to shop in Amazon's Deals Store. If you're tired of having way too many devices and not enough outlets, Amazon shoppers swear by a gadget that just so happens to be marked down — it's still on sale for its Prime Day price. The One Beat 6-Plug Surge Protector Outlet Extender has more than 12,900 reviews — and it's on sale for $16. That's 36 per cent off, and the lowest price I've ever seen. The only catch? You need a Prime membership — sign up for a free trial here if you don't have one already. Scroll down for all the details. Quick shop: 36% off The details The One Beat 6-Plug Surge Protector Outlet Extender features six AC outlets that can fit three-prong and two-prong plugs, two USB-A ports and one USB-C port. So, you can charge and use up to nine devices at the same time. With a swivel design and built-in surge protection, the power bar not only allows you to plug in multiple gadgets at once but also protects them from electrical spikes. The power bar is a bestseller on Amazon, with more than 3,000 shoppers snapping one up in the past month. The power bar has a three-sided design that helps to avoid crowding plugs together. It can also swivel 180 degrees to make plugging in devices easier. It also offers protection against power surges, giving you peace of mind that your devices will be protected from electrical spikes. What reviewers are saying 🛍️ 12,900+ ratings ⭐ 4.6/5 stars 🏅 "Didn't know how much I needed this." Amazon shoppers love the power strip for its convenience and usefulness, with over 70 per cent of reviewers giving the item a five-star rating. One shopper, who called the power bar "flexible and convenient," said it allows them to "plug in multiple traditional as well as USB cords," also noting that the swivel function lets them position the power bar "virtually any way" they need. Another person wrote that the power strip was "great for maximizing" outlets, especially for those who may only have a few in their home. Another reviewer called the item an "absolute lifesaver," writing that the compact design and swivel make the power strip "incredibly versatile for use in any space." However, while most shoppers were happy with the power bar, some had issues with its stability. One shopper, who said that the power strip "works great," wrote that one improvement they'd like to see is the ability to "lock the position of the rotating plug," but also thought that this was an issue of "aesthetics rather than function." The verdict If you're looking for a versatile power bar that also offers surge protection, the One Beat 6-Plug Surge Protector Outlet Extender could be a game-changer. The power bar makes it easy to charge and power multiple devices, including those that use USB-A and USB-C connections. It's great for use in tight spaces to avoid bending plugs and for maximizing the use of outlets in homes without many power outlets. With tons of glowing reviews and a solid price, it's definitely worth trying out for yourself.
Yahoo
40 minutes ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Molina Healthcare, Inc. (MOH) Wins Major Medicaid Contracts in 4 States
We recently compiled a list of Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care provider offering government-sponsored healthcare programs like Medicaid and Medicare to low-income individuals and families across the U.S. Headquartered in Long Beach, California, Molina operates health plans in multiple states and serves millions through Medicaid, Medicare, and dual-eligible Special Needs Plans (D-SNPs). The company recently secured major Medicaid contract wins and renewals in states like Georgia, Idaho, Massachusetts, and Ohio, which will contribute to revenue growth and expand access to care. Molina Healthcare, Inc. (NYSE:MOH) also acquired ConnectiCare Holding Co., adding 140,000 members, and previously took over Bright Health's assets in California. A key strategic focus is the dual-eligible population, those covered by both Medicaid and Medicare, due to their complex needs and potential for integrated, high-quality care. Molina is developing blended service models and adjusting policy and reimbursement structures to address this growing segment. A healthcare professional wearing a health communications device discussing patient data with a colleague. Molina Healthcare, Inc. (NYSE:MOH) remains active in community engagement, such as maternal health initiatives in Texas. It's also prioritizing behavioral health and chronic condition management through updated protocols and external partnerships. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
